<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: In type 2 diabetic patients at low risk for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>), the relationship between the clinical course of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> by stage of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> (CKD) and <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> remains unclear </plain></SENT>
<SENT sid="1" pm="."><plain>Clarification of this relationship is important for clinical decision-making for both low- and high-risk diabetic patients </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: This 4 year prospective study enrolled 2,954 type 2 diabetic patients with no prevalent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>, and serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> &lt;176.8 μmol/l </plain></SENT>
<SENT sid="3" pm="."><plain>The risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> (non-fatal and fatal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and <z:hpo ids='HP_0001297'>stroke</z:hpo>, and <z:hpo ids='HP_0004950'>peripheral arterial disease</z:hpo>) was assessed according to CKD stage categorised by urinary albumin-to-<z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio (ACR; mg/mmol) and estimated GFR (eGFR; ml min(-1) 1.73 m(-2)) </plain></SENT>
<SENT sid="4" pm="."><plain>Association of progression from 'no CKD' stage (ACR &lt;3.5 mg/mmol and eGFR ≥ 90 ml min(-1) 1.73 m(-2)) with risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> was also evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: During follow-up (median 3.8 years), 89 CVD events occurred </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with patients with 'no CKD' as reference, those with ACR ≥ 35.0 mg/mmol with co-existing eGFR 60-89 ml min(-1) 1.73 m(-2) or &lt;60 ml min(-1) 1.73 m(-2) showed increased risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo>, whereas those with eGFR ≥ 90 ml min(-1) 1.73 m(-2) did not </plain></SENT>
<SENT sid="7" pm="."><plain>Those with ACR &lt;3.5 mg/mmol and eGFR &lt;60 ml min(-1) 1.73 m(-2) did not show any increased risk </plain></SENT>
<SENT sid="8" pm="."><plain>Among patients with 'no CKD' stage at baseline, those who progressed to ACR ≥ 3.5 mg/mmol during follow-up showed an increased risk compared with those who did not, whereas those who progressed to eGFR &lt;90 ml min(-1) 1.73 m(-2) did not have increased risk </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: The risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> was associated with progression of <z:mp ids='MP_0002871'>albuminuria</z:mp> stage rather than eGFR stage in type 2 diabetic patients at relatively low risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
</text></document>